SOUTH SAN FRANCISCO, Calif. / Sep 03, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 beginning at 7 a.m. Eastern Time.
A webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com.
About Quince Therapeutics
Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, X, and YouTube.
| Last Trade: | US$1.61 |
| Daily Change: | 0.03 1.90 |
| Daily Volume: | 72,815 |
| Market Cap: | US$86.470M |
September 02, 2025 July 16, 2025 June 18, 2025 June 03, 2025 May 13, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
